An observational study in Hypoxia, sponsored by Mayo Clinic. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Mayo Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 269 studies in Hypoxia with a site in United States — 36 open to participants now, 51 under way, 2 of them phase 3. Hypoxia · United States.
Among the 269 studies in Hypoxia with a site in United States, this one is the 43rd largest by enrollment of the 87 observational ones that give a count, is one of 16 that started in 2025, is one of 87 observational ones, and was the 249th registered.
1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.
Browse Hypoxia studies →36 of the 269 studies in Hypoxia with a site in United States are open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 7 days–30 days
Thomas Jefferson University · Sites in United States
Ages 18+ · Healthy volunteers
Joseph C. Wu · Sites in United States
Ages 40+
Zev Rymer · Sites in United States
Ages 18+
Wayne State University · Sites in United States
Ages 18–85 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
269 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 41 · Phase 2 26 · Phase 3 9 · Phase 4 8
First in 1999; this study’s year is marked. 16 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 79 across 279 observational studies indexed under Hypoxia.
Median enrollment 30 across the 181 interventional studies, 30 across the 87 observational. Of the 190 that completed or were terminated, 67 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 269 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
Mayo Clinic has 4 studies filed under Hypoxia — fewer than ten, so there is no comparison to draw.
18 of the studies in Hypoxia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06417177University of Missouri-ColumbiaImpact of Early Aging and Menopause on the Vascular Responses to Hypoxia | 2026-12 |
| NCT06692400Loma Linda UniversityThe Effects of Endotracheal Suctioning on Pain and Serum Markers | 2026-12 |
| NCT07002437University of FloridaHypoxia Pathways for Early Recovery After Spinal Cord Injury | 2026-12 |
| NCT07408388Nihon KohdenPulse Oximeter Accuracy During Stable Hypoxia Plateaus | 2026-12-01 |
| NCT06040268University of Colorado, DenverAdvair HFA in Healthy and HAPE Predisposed Subjects | 2026-12-01 |
Add all 18 to your calendar (.ics) → With an account.
Among the 269 studies in Hypoxia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to develop a single, standardized test to determine how individuals tolerate acute hypoxia in a stepwise fashion. We aim to evaluate the association between multiple factors, such as ventilatory compensation, heart rate response, acid-base changes, sex, pulmonary function, etc, which may explain why some individuals tolerate exercise in hypoxia better than others. Identifying these factors of association will inform future pharmacological and non-pharmacological attempts to combat acute hypoxic exercise.
A total of 50 participants (25 female, 25 male) will be recruited for this study. Participants will be recruited from the general population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50 participants (25 female, 25 male) who are physically active for at least 150 minutes per week, at a moderate activity level.
Diagnostic Test: Graded Exercise Test · Diagnostic Test: Graded Hypoxia Exercise Test
Participants will perform a graded exercise test on either a cycle ergometer or treadmill. The testing protocol will begin with a 5- 10 min warm-up of either cycling or running/walking at the participants preferred pace. If the graded exercise test is on a bike, exercise will begin at wattage that elicits \~50% of their heart rate max, HRmax = 208 - 0.7 × age and increase by either 10W, 15W, or 20W every two minutes in a stepwise fashion until symptom limitation. The step of the wattage increase will be at the discretion of the investigators. If the graded exercise test is on a treadmill, the test will begin at a speed that elicits \~50% of predicted HRmax. Following, the speed of the treadmill will increase 0.5 mph (0.8 km/hr) every two minutes in a stepwise fashion until symptom limitation. If the participant maxes out the speed of the treadmill, we will increase the grade 2% every 2-minutes until symptom limitation.
Participants will perform a single constant work rate exercise tests during graded hypoxia. They will be outfitted with either a facemask or mouthpiece connected to a uni-directional breathing valve. During inspiration, subjects will breathe from a closed-system Douglas bag balloon reservoir (\~200 L) connected to the value on the inspired side via air-tight clean-bor tubing. The participant will complete the same mode of exercise as they did during visit 1, either bike or treadmill. The resistance on the bike or incline of the treadmill will be set to elicit an intensity equivalent to \~50% of their V̇O2max determined during visit 1. Participants will complete 5-minute stages over a range of FiO2 values. The exercise test will begin in an FiO2=0.21 (i.e. room air). Following this first 5-min stage the FiO2 will increase to 0.25, afterwards, participants will complete another stage at FiO2=0.21 and then decrease in a stepwise fashion every 5-minutes.
PaO₂/FiO₂ Ratio
The PaO₂/FiO₂ ratio is a widely used measure of oxygenation efficiency in the lungs. It compares the arterial oxygen partial pressure (PaO₂, measured in mmHg) to the fraction of inspired oxygen (FiO₂, expressed as a decimal). The ratio provides insight into the ability of the lungs to transfer oxygen into the bloodstream. A PaO₂/FiO₂ ratio of 300-400 is considered to be mild hypoxemia. Participants are considered as poorly tolerating hypoxia if their ratio is \<400 and good at tolerating hypoxia if their ratio is \>400.
Time frame: 30 minutes
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in Jul 2025, 3 months.
Of 125 non-industry observational studies under Hypoxia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 74. This study's 3 months is below that.
Counting every sponsor, half of 155 studies reached it within 14 months; a quarter within 3 and three quarters within 46.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Apr 2027 → Jul 2025 and completion Apr 2028 → Sep 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.